title: Multiple Myeloma Gets Three New Drugs.
abstract: In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.
authors.forename: Alissa
authors.initials: A
authors.lastname: Poh
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000378:metabolism; D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D001896:Boron Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001896:Boron Compounds; D008562:Membrane Glycoproteins; C546027:elotuzumab; C556306:daratumumab; C548400:ixazomib; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D005998:Glycine